Advisory Committee
Associate Professor Brian Hawkett
Scientific Advisor
Brian is the Director of the Key Centre for Polymers and Colloids (KCPC) situated in the Department of Chemistry at the University of Sydney. He is also a member of the University of Sydney NanoInstitute. Brian is one of the world’s foremost experts in the use of RAFT in disperse phase systems and has used this expertise over the years to develop real world solutions in a diverse range of fields including medicine, aerospace, agrochemistry, speciality coatings (including paints) and the mining industry.
Brian obtained his PhD in chemistry from the University of Sydney in 1980 and then went on to work in several technical management positions in companies such as Berger Paints, ICI Specialty Chemicals, Daratech and as an independent consultant before finally returning back to USyd as Principal Research Fellow. His research group in the KCPC is responsible for the key intellectual property that underpins Zeta’s nanotechnology platform and they continue to work closely with the Zeta team.
Clinical Associate Professor Trevor Tejada-Berges
Clinical Advisor
Trevor is Staff Specialist in Gynaecological Oncology at the Chris O’Brien Lifehouse in Sydney, Australia. He is a Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, a Fellow of The American Congress of Obstetricians and Gynecologists and a Fellow of the Royal College of Physicians of Canada. He is Board-certified in both Obstetrics and Gynecologic Oncology by the American College of Obstetrics and Gynecology.
Associate Professor Viive Howell
Scientific Advisor
Viive is the Research Director of the Bill Walsh Translational Cancer Research Laboratory, Kolling Institute, Royal North Shore Hospital (RNSH) and Associate Professor, Northern Clinical School, Faculty of Medicine and Health, University of Sydney. Viive is a molecular geneticist with expertise in pre-clinical modelling. Her research encompasses a number of cancers including brain, ovarian, lung, mesothelioma, pancreatic and colorectal. She is establishing preclinical pipelines for these cancers to test new therapeutics alone or in combination with radiotherapy or chemotherapy.
Working closely with clinical and surgical colleagues the goal of this research is to fast-track efficacious regimens to clinical trials, identify prognostic and predictive biomarkers and determine strategies to overcome chemoresistance.
Viive received her PhD in Molecular Medicine from the University of Sydney in 2005. Prior to her current appointments she was a Cancer Institute NSW Northern Translational Research Fellow, Cancer Institute NSW Fellow and NHMRC CJ Martin Fellow at the University of Michigan, USA and the University of Sydney.
Erik Strautnieks
Quality And Regulatory Affairs Advisor
Erik is a qualified Quality Assurance leader, with over 30 years of commercial experience in medical, automotive and manufacturing industries with domestic and global organisations. He was the Director of Global Quality Assurance for Sirtex Medical Ltd from 2006 -2017. During his time at Sirtex he was responsible for designing and maintaining the corporate Quality Management System for all global locations compliant with all major regulatory jurisdictions including Australia, Europe, USA, Canada, Brazil and many Asian countries. He had responsibility for managing product release, assessment and justification of manufacturing deviations, all Quality Control processes and validations as well as establishing risk management policies and overseeing the process of corporate risk management.
